KYNU

Protein identityUniProt · HPA

UniProt accession

Q16719

Gene

KYNU

Ensembl

ENSG00000115919

Chromosome

2

Canonical length

465 aa

Protein class

Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins

Subcellular location

Nucleoplasm,Cytosol

Quaternary structure

Homodimer

OverviewNCBI Gene

Kynureninase is a pyridoxal-5'-phosphate (pyridoxal-P) dependent enzyme that catalyzes the cleavage of L-kynurenine and L-3-hydroxykynurenine into anthranilic and 3-hydroxyanthranilic acids, respectively. Kynureninase is involved in the biosynthesis of NAD cofactors from tryptophan through the kynurenine pathway. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2010]

Canonical amino-acid sequenceUniProt

465 residues, UniProt reviewed canonical sequence.

>Q16719|KYNU
     1  MEPSSLELPA DTVQRIAAEL KCHPTDERVA LHLDEEDKLR HFRECFYIPK IQDLPPVDLS
    61  LVNKDENAIY FLGNSLGLQP KMVKTYLEEE LDKWAKIAAY GHEVGKRPWI TGDESIVGLM
   121  KDIVGANEKE IALMNALTVN LHLLMLSFFK PTPKRYKILL EAKAFPSDHY AIESQLQLHG
   181  LNIEESMRMI KPREGEETLR IEDILEVIEK EGDSIAVILF SGVHFYTGQH FNIPAITKAG
   241  QAKGCYVGFD LAHAVGNVEL YLHDWGVDFA CWCSYKYLNA GAGGIAGAFI HEKHAHTIKP
   301  ALVGWFGHEL STRFKMDNKL QLIPGVCGFR ISNPPILLVC SLHASLEIFK QATMKALRKK
   361  SVLLTGYLEY LIKHNYGKDK AATKKPVVNI ITPSHVEERG CQLTITFSVP NKDVFQELEK
   421  RGVVCDKRNP NGIRVAPVPL YNSFHDVYKF TNLLTSILDS AETKN

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against KYNU can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability

Intracellular

Secreted

No

Transmembrane segments

0

Mean surface accessibility (rSASA)

0.23

Highest tissue expression

83 nTPM

Expression across tissuesHPA

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about KYNU.

Disease | AllUniProt

Conditions KYNU is implicated in, by any mechanism.

• Hydroxykynureninuria (HYXKY) MIM:236800
• Vertebral, cardiac, renal, and limb defects syndrome 2 (VCRL2) MIM:617661

Disease | GeneticClinVar

24 pathogenic / likely-pathogenic of 133 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

• Vertebral, cardiac, renal, and limb defects syndrome 2
• Congenital NAD deficiency disorder
• KYNU-related disorder
• Catel-Manzke syndrome
• Hydroxykynureninuria

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)

1.35

gnomAD pLI

0

gnomAD missense Z

-0.41

DepMap mean gene effect

-0.06

DepMap dependency class

selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

• 'de novo' NAD+ biosynthetic process from L-tryptophan
• anthranilate metabolic process
• L-kynurenine catabolic process
• L-tryptophan catabolic process
• L-tryptophan catabolic process to kynurenine
• NAD+ biosynthetic process
• quinolinate biosynthetic process
• response to type II interferon
• response to vitamin B6

Molecular functions

• protein homodimerization activity
• pyridoxal phosphate binding
• kynureninase activity

Cellular components

• cytoplasm
• cytosol
• mitochondrion
• nucleoplasm

Protein domainsUniProt · Pfam · InterPro

• Pyridoxal phosphate-dependent transferase, major domain
• Pyridoxal phosphate-dependent transferase, small domain
• Pyridoxal phosphate-dependent transferase
• Kynureninase
• Kynureninase C-terminal domain

KeywordsUniProt

• Acetylation
• Cytoplasm
• Hydrolase
• Pyridine nucleotide biosynthesis
• Pyridoxal phosphate